ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$23.76 USD
-0.03 (-0.13%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $23.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for ArriVent BioPharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -69.33 | -36.91 | -51.61 | NA | NA |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | NA | NA |
Net Change from Assets/Liabilities | 12.60 | -7.15 | -3.94 | NA | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | NA | NA |
Other Operating Activities | 0.90 | 0.42 | 42.96 | NA | NA |
Net Cash From Operating Activities | -55.84 | -43.63 | -12.59 | NA | NA |
Property & Equipment | 0.00 | 0.00 | 0.00 | NA | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | NA | NA |
Investments | 0.00 | 0.00 | 0.00 | NA | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | NA | NA |
Net Cash from Investing Activities | 0.00 | 0.00 | -40.00 | NA | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 45.27 | 169.72 | 89.87 | NA | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | NA | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | NA | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | NA | NA |
Other Financing Activities | -2.41 | 0.00 | 0.00 | NA | NA |
Net Cash from Financing Activities | 42.86 | 169.72 | 89.87 | NA | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | NA | NA |
Net Change In Cash & Equivalents | -12.98 | 126.09 | 37.28 | NA | NA |
Cash at Beginning of Period | 163.37 | 37.28 | 0.00 | NA | NA |
Cash at End of Period | 150.39 | 163.37 | 37.28 | NA | NA |
Diluted Net EPS | -32.38 | -28.90 | NA | NA | NA |
Fiscal Year End for ArriVent BioPharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -39.29 | -17.42 | -69.33 | NA | -33.74 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Net Change from Assets/Liabilities | 0.19 | -1.84 | 12.60 | NA | 7.89 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Operating Activities | 1.39 | 0.63 | 0.90 | NA | 0.36 |
Net Cash From Operating Activities | -37.72 | -18.63 | -55.84 | NA | -25.49 |
Property & Equipment | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | NA | -25.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | NA | -25.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 186.00 | 185.63 | 45.27 | NA | 44.95 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -2.41 | NA | 0.00 |
Net Cash from Financing Activities | 186.00 | 185.63 | 42.86 | NA | 44.95 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Net Change In Cash & Equivalents | 148.28 | 167.00 | -12.98 | NA | -5.54 |
Cash at Beginning of Period | 150.39 | 150.39 | 163.37 | NA | 163.37 |
Cash at End of Period | 298.67 | 317.39 | 150.39 | NA | 157.83 |
Diluted Net EPS | -0.65 | -0.70 | NA | NA | NA |